Fina Biosolutions LLC is a privately held research and development stage biotechnology company that discovers, develops, and collaborates to commercialize novel vaccine conjugates for prevention of life-threatening diseases. Fina has patented novel techniques to conjugate, purify, and manufacture conjugates using its proprietary chemistry to create complex conjugate vaccines. The technology is currently licensed by leading vaccine manufacturers in both Europe and Asia, including GlaxoSmithKline for marketed vaccines Synflorix™ Menitorix™, Nimenrix™, The Serum Institute of India Ltd., The Chengdu Institute of Biological Products and others. Fina Biosolutions also manufactures E. coli expressed CRM197 conjugate vaccine carrier protein. Fina BioSolutions also develops polymer based diagnostic reagents, amino dextran, and antibody dextran conjugates.
| Website | http://www.finabio.com |
| Employees | 11 (8 on RocketReach) |
| Founded | 2006 |
| Technologies |
JavaScript
,
HTML
,
PHP
+18 more
(view full list)
|
| Industry | Biotechnology Research |
| Keywords | Novel Vaccines, Biotechnology Research, Vaccine Development, Life Threatening Diseases, Pharmaceutical Research, Disease Prevention, Biotech, Immunology Research, Therapeutic Vaccines, Drug Development, Vaccine Technology, Clinical Development, Pharmaceutical, Biologics, Immunotherapy, Research And Development, Drug Discovery, Biomedical Research |
| Competitors | Genentech, Amgen, Regeneron, Gilead Sciences, Vertex Pharmaceuticals, Illumina, Biogen, Receptos, a wholly-owned subsidiary of Celgene, CRISPR Therapeutics, Editas Medicine +36 more (view full list) |
Looking for a particular Fina BioSolutions LLC employee's phone or email?
Andrew Lees is the CEO and Owner of Fina BioSolutions LLC.
8 people are employed at Fina BioSolutions LLC.